Trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: results from DESTINY-Breast02
Compared with physician’s choice treatment, trastuzumab deruxtecan shows a favorable benefit-risk profile in patients with HER2+ metastatic breast cancer